Keros Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
KROS$9.17-2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| YEAR ENDED DECEMBER 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| REVENUE: | |||
| Service and other revenue | $550 | $151 | $— |
| License revenue | 3,000 | — | — |
| Total revenue | 3,550 | 151 | — |
| OPERATING EXPENSES: | |||
| Research and development | (173,629) | (135,258) | (87,265) |
| General and administrative | (40,754) | (34,834) | (27,525) |
| Total operating expenses | (214,383) | (170,092) | (114,790) |
| LOSS FROM OPERATIONS | (210,833) | (169,941) | (114,790) |
| OTHER INCOME (EXPENSE), NET: | |||
| Interest expense, net | — | — | (1) |
| Research and development incentive income | 1,238 | 2,400 | 7,081 |
| Dividend income | 23,496 | 14,755 | 3,644 |
| Other expense, net | (954) | (206) | (613) |
| Total other income (expense), net | 23,780 | 16,949 | 10,111 |
| Loss before income taxes | (187,053) | (152,992) | (104,679) |
| Income tax provision | (300) | — | — |
| Net loss | $(187,353) | $(152,992) | $(104,679) |
| Net loss attributable to common stockholders—basic and diluted | $(187,353) | $(152,992) | $(104,679) |
| Net loss per share attributable to common stockholders—basic and diluted | $(5.00) | $(5.20) | $(4.15) |
| Weighted-average common stock outstanding—basic and diluted | 37,437,652 | 29,447,119 | 25,241,030 |
Consolidated Statements of Stockholders’ Equity
| COMMON STOCK$0.0001 PAR VALUE · ADDITIONALPAID-INCAPITAL · ACCUMULATEDDEFICIT · TOTAL STOCKHOLDERS’ EQUITY | |||||
|---|---|---|---|---|---|
| SHARES · AMOUNT | |||||
| BALANCE, January 1, 2022 | 23,974,834 | $2 | $366,927 | $(123,755) | $243,174 |
| Issuance of common stock under the ATM agreement, net of commissions and offering cost of $1,971 | 3,410,384 | — | 119,428 | — | 119,428 |
| Exercise of common stock options | 158,235 | — | 818 | — | 818 |
| Stock-based compensation | — | — | 18,682 | — | 18,682 |
| Net loss | — | — | — | (104,679) | (104,679) |
| BALANCE, December 31, 2022 | 27,543,453 | $2 | $505,855 | $(228,434) | $277,423 |
| Issuance of common stock under the ATM agreement, net of commissions and offering cost of $2,708 | 4,061,606 | 1 | 175,793 | — | 175,794 |
| Exercise of common stock options | 236,025 | — | 3,225 | — | 3,225 |
| Stock-based compensation | — | — | 28,763 | — | 28,763 |
| Net loss | — | — | — | (152,992) | (152,992) |
| BALANCE, December 31, 2023 | 31,841,084 | $3 | $713,636 | $(381,426) | $332,213 |
| Issuance of common stock, net of underwriting discounts, commissions and offering costs of $9,943 | 4,025,000 | — | 151,057 | — | 151,057 |
| Issuance of common stock under the ATM agreement, net of commissions and offering cost of $3,655 | 4,290,096 | 1 | 228,622 | — | 228,623 |
| Exercise of common stock options | 398,525 | — | 12,141 | — | 12,141 |
| Stock-based compensation | — | — | 34,872 | — | 34,872 |
| Net loss | — | — | — | (187,353) | (187,353) |
| BALANCE, December 31, 2024 | 40,554,705 | $4 | $1,140,328 | $(568,779) | $571,553 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.